Trending News

Scales showing a comparison between Mounjaro and Ozempic
#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

New data show Zepbound/Mounjaro superior to Wegovy for weight loss

Eli Lilly’s Zepbound/Mounjaro (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy (semaglutide, also known as Ozempic), according to topline results from the SURMOUNT-5 Phase IIIb clinical trial.  On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. … Read More

#News #Trending News

#Applied Therapeutics #CNS #FDA #Genetic diseases #Rare disease

Patient groups urge FDA to reconsider govorestat rejection

The US Food and Drug Administration’s (FDA) decision not to approve govorestat, a central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI) for Classic Galactosemia, has been met with criticism from patient groups.  Govorestat is the only investigational treatment to be evaluated for Galactosemia, a rare genetic disease that can be… Read More

#News #Regulatory #Trending News

Woman reaches for inhaler
#Asthma #AstraZeneca #King's College London #Phase II trial

First new treatment for asthma attacks in 50 years

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%, according to a UK study.  The findings, published in The Lancet Respiratory Medicine, could… Read More

#News #Trending News

#Epigenetics #Genetics / genomics #Oxford Nanopore Technologies #UK Biobank #UK government

UK partners to create world’s largest epigenetic dataset

A world-first ‘epigenetic map’ of the human genome could lead to breakthroughs in new diagnoses and treatments, say UK scientists.  This new resource for medical researchers will be created though a new strategic partnership between the UK government, Oxford Nanopore Technologies, UK Biobank, NHS England and Genomics… Read More

#News #Trending News

Roche headquarters
#CAR-T #Cell therapy #Mergers and acquisitions #Poseida Therapeutics #Roche

Roche buys CAR-T specialist Poseida Therapeutics for $1.5bn

Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.  Roche will acquire the company for $9 per share in cash at closing, representing a total equity value of approximately $1 billion.  Stockholders would also receive a non-tradeable contingent… Read More

#Business & Investment #News #Trending News

Stomach pain
#Chronic pain #Irritable Bowel Syndrome #Painkillers #Peptides #University of Queensland

Highly promising new oral approach to abdominal pain

University of Queensland (UQ) researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin. The team changed the chemical structure of oxytocin to make it gut-stable after earlier work revealed the hormone could treat… Read More

#News #Trending News

Hydrogel
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Bacteria #Chalmers University of Technology #Hydrogel

Hydrogel enhances antibiotics’ effect against resistant bacteria

New research has shown that resistant bacteria can regain susceptibility to antibiotics when the treatment is combined with a material equipped with antibacterial peptides. The study, performed in a laboratory environment, shows that antibiotics can achieve a 64-fold increase in bactericidal effect when used together with… Read More

#News #Trending News

CAR-T therapy
#Autoimmune disease #CAR-T #Kyverna Therapeutics #Lupus

CAR-T therapy for lupus nephritis “resets the immune system”

Kyverna Therapeutics has revealed plans to present updated clinical data from lupus nephritis (LN) patients treated with KYV-101 at the American College of Rheumatology (ACR) Covergence 2024. The data are from the ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments. Read More

#News #Trending News

CAR-T therapy for leukaemia
#Autolus #CAR-T #Cell therapy #FDA #Immunotherapy #Leukaemia #Oncology

First FDA approval for new CAR-T therapy

The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy of obecabtagene autoleucel was evaluated in FELIX, an open-label, multicentre, single-arm trial that enrolled adults… Read More

#News #Regulatory #Trending News

Circular DNA concept
#Cancer Grand Challenges #DNA #Oncology #The Francis Crick Institute #University College London

Targeting circular DNA could treat the most aggressive cancers

Scientists have discovered a way to target elusive circular fragments of DNA that drive the survival of some of the most aggressive cancers, paving the way for future treatments. In three papers published today in Nature, scientists from the Cancer Grand Challenges team eDyNAmiC and their… Read More

#Cancer Research #News #Trending News

Mosquito against yellow background
#Covalent kinase inhibitors #Malaria #Medicines for Malaria Venture #Quotient Sciences #University of Glasgow

Two new studies advance the treatment of malaria

In two separate studies, malaria researchers are exploring the potential of a long-acting injectable preventive compound and an approach from cancer treatments that could be used as a single-dose cure. Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for their… Read More

#News #Trending News

Kidneys
#Clinical trial #Kidney disease #Nephrology #Takeda #Vera Therapeutics

Positive news for IgAN treatment presented at Kidney Week

Positive data from two trials in immunoglobulin A nephropathy (IgAN) were shared at the American Society of Nephrology Kidney Week 2024 in San Diego, California. Vera Therapeutics announced data from its ORIGIN Phase IIb trial of atacicept that showed stabilised kidney function through 96 weeks of… Read More

#News #Trending News

Great British Pounds, Investment
#ABPI #Life sciences #UK budget #UK economy #UK government

UK Chancellor backs life sciences in the Budget

The UK’s Labour Government has announced its first budget, which focuses on stability, investment, and long-term growth. Key announcements in the Budget included increases in NHS funding, a £520m life sciences innovative manufacturing fund, and investment in research and development, including increased funding for the National… Read More

#News #Trending News

Monkeypox virus
#Immunology / Virology & Vaccines #Monkeypox #Monkeypox vaccine #NIAID #Outbreak

Mpox vaccine found to be safe and effective in adolescents

A clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults. The interim results of this National Institutes of Health (NIH)-funded trial were presented at the IDWeek2024 conference in Los Angeles. Colourised transmission… Read More

#News #Trending News

Cancer cell
#Cancer drug targets #Drug resistance #EMBL European Bioinformatics Institute #Gene mutation #Genetics / genomics #Oncology #Wellcome Sanger Institute

Drug resistance study boosts discovery of next-generation cancer drugs

New research has detailed each type of cancer mutation that causes drug resistance, helping to uncover targets for drug development and identify potential effective second-line therapies. In a new large-scale study, researchers from the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), Open Targets, and collaborators… Read More

#Cancer Research #News #Trending News

Antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Immunology / Virology & Vaccines #World Health Organization

Better use of vaccines will reduce AMR deaths, report finds

Vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% every year, according to a new report by the World Health Organization (WHO). While some of these vaccines are already available but underused, others would need to be developed and brought to the… Read More

#News #Trending News